0001415889-22-008895.txt : 20220819 0001415889-22-008895.hdr.sgml : 20220819 20220819160555 ACCESSION NUMBER: 0001415889-22-008895 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220817 FILED AS OF DATE: 20220819 DATE AS OF CHANGE: 20220819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Young Diane C. CENTRAL INDEX KEY: 0001648010 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 221180805 MAIL ADDRESS: STREET 1: 175 TOYOTA PLAZA, 7TH FLOOR CITY: MEMPHIS STATE: TN ZIP: 38103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 form4-08192022_010835.xml X0306 4 2022-08-17 0000744218 Celldex Therapeutics, Inc. CLDX 0001648010 Young Diane C. C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 false true false false SVP, CHIEF MEDICAL OFFICER Common Stock 2022-08-17 4 M 0 19000 10.38 A 21115 D Common Stock 2022-08-17 4 S 0 19000 37.3008 D 2115 D Common Stock 2022-08-17 4 M 0 45000 2.71 A 47115 D Incentive Stock Option 10.38 2022-08-17 4 M 0 19000 0 D 2030-06-18 Common Stock 19000 48400 D Incentive Stock Option 2.71 2022-08-17 4 M 0 45000 0 D 2029-07-08 Common Stock 45000 15000 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.30 to $37.35 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. 25% vested on July 8, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. /s/ Sam Martin, attorney-in-fact for Diane C. Young 2022-08-19